Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473462 | 1.00 | EPHX1 (0.50) | EPHX1BTKGAAKDM1AMAOB | |
| SCHEMBL1406894 | 0.86 | BTK (0.61) | EPHX1BTKGAAKDM1AMAOB | |
| SCHEMBL10343938 | 0.86 | BTK (0.61) | EPHX1BTKGAAKDM1AMAOB | |
| SCHEMBL3702152 | 0.86 | BTK (0.61) | EPHX1BTKGAAKDM1AMAOB | |
| SCHEMBL3702157 | 0.86 | BTK (0.61) | EPHX1BTKGAAKDM1AMAOB | |
| Methyl Alcohol SCHEMBL28082230 | 0.84 | BTK (0.59) | EPHX1BTKGAAKDM1AMAOB | |
| SCHEMBL20893335 | 0.82 | BTK (0.58) | EPHX1BTKGAAKDM1AMAOB | |
| Bicarbonate SCHEMBL187492 | 0.82 | BTK (0.62) | EPHX1BTKGAAKDM1AMAOB | |
| SCHEMBL20445292 | 0.82 | NPSR1 (0.60) | EPHX1BTKGAAKDM1AMAOB | |
| SCHEMBL12439739 | 0.81 | BTK (0.53) | EPHX1BTKGAAKDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109790157-A | New antimicrobial compound | 方济各安吉利克化学联合股份有限公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-109415373-A | New antimicrobial compound | 方济各安吉利克化学联合股份有限公司 | 2019-03-01 | — | — | CN | disclosed |
| EP-3019492-B1 | AMILORIDE-TYPE COMPOUNDS AS INHIBITORS IN EPITHELIAL SODIUM CHANNELS FOR THE TREATMENT OF DISEASES OF THE LUNGS AND AIRWAYS | BOEHRINGER INGELHEIM INT (DE) | 2017-09-06 | — | — | EP | disclosed |
| EP-3019492-A1 | AMILORIDE-TYPE COMPOUNDS AS INHIBITORS IN EPITHELIAL SODIUM CHANNELS FOR THE TREATMENT OF DISEASES OF THE LUNGS AND AIRWAYS | Boehringer Ingelheim International GmbH (DE) | 2016-05-18 | — | — | EP | disclosed |
| US-9126982-B2 | Heterocyclic compounds, medicaments containing them, use and processes for the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-08 | — | — | US | disclosed |
| US-8962622-B2 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC (US) | 2015-02-24 | — | — | US | disclosed |
| WO-2015003958-A1 | AMILORIDE-TYPE COMPOUNDS AS INHIBITORS IN EPITHELIAL SODIUM CHANNELS FOR THE TREATMENT OF DISEASES OF THE LUNGS AND AIRWAYS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-15 | — | — | WO | disclosed |
| US-20150011535-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING THEM, USE AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| EP-2066319-B1 | BENZOTRIAZOLE KINASE MODULATORS | HOFFMANN LA ROCHE (CH) | 2012-02-01 | — | — | EP | disclosed |
| US-20080103142-A1 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011535-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING THEM, USE AND PROCESSES FOR THE PREPARATION THEREOF | SCNN1B, SCNN1A, TRPM5 | EPHX1 1974/4885BTK 2621/4885GAA 734/4885 |
| US-20080103142-A1 | Benzotriazole kinase modulators | CDK1, CDK3, MAPK1 | EPHX1 4028/4885BTK 297/4885GAA 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.